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IN a short-term study we had shown that a significant fall in the average daily
blood sugar level on the second day of treatment is a valuable criterion of future
response of the diabetic patient to chlorpropamide and that a maximum fall
occurs by the eighth-tenth day of treatment (Grant and Boyd, 1960).
On the basis of a longer period of surveillance it was decided to investigate
any relationship the blood sugar taken at an early stage of treatment might bear
to the final assessment after three months' review. In routine practice it was
hoped that one single blood sugar estimation done on a certain day of treatment
might be sufficiently reliable in predicting the outcome of chlorpropamide
treatment.
MATERIALS AND METHODS.
Forty diabetic patients diagnosed after the age of 40 years were studied.
Estimations of true blood glucose were perforined on venous blood by a
modification of the anthrone method of Handelsman and Sass (1956). Blood
samples were drawn at 7.30 a.m. (fasting B.S.L.) and at 4.30 p.m. and 8.30 p.m.
The mean of these three readings was taken as the average daily blood sugar
level (B.S.L.) for the day concerned.
After an initial five days on diet alone (control period), during which blood
sugars were taken as stated, the patients were started on chlorpropamide 500 mgs.
as a single morning dose. Following the first five days of treatment blood
samples were again drawn inclusive of the sixth-tenth days of treatment;
designated the treatment period. The mean values for all the blood sugars during
the two periods observed were calculated for each patient (control period B.S.L.
inean and treatmient period B.S.L. mean). These levels were ulsed for statistical
analysis by scatter diagram, any correlation being compared with the patient's
response category after three months' treatment.
The criteria of response to chlorpropamide treatment used were modified from
those of Cardonnet, et al. (1959), and Sugar, et al. (1949), being the same response
categories previously set out (Boyd and Grant, 1960).
Figure 1 shows the points of intersection made by the control period mean
B.S.L. and the treatment period B.S.L. mean on the X and Y axis respectively
for each patient. An obvious relationship to the patient's response category was
apparent. All diabetics showing an excellent or good response to 500 mgs. of
chlorpropamide fell into a rectangle with the following boundaries-140 to
430 mg./100 ml. along the X axis and 70 to 165 mg./100 ml. along the Y axis.
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Fig. 1-Comparison of the mean control B.S.L. and mean treatment B.S.L. on
chlorpropamide 500 mg. daily in forty patients whose final assessment after three
months is shown by symbols.
CLINIcAL RESPONSE.
Excellent or Good Group: Intermediate Group: Failures:
* Still on chlorpropamide. X Fair control. O With ketosis.
O Off chlorpropamide. * Poor control. 0 Without ketosis.
Patients with only fair control or poor control as well as failures either ketotic
or non-ketotic had points which fell outside 250 mg./100 ml. on the X axis
and above 170 mg./100 ml. on the Y axis.
From this observation two conclusions were reached; Firstly the control period
B.S.L. means if high are not necessarily an indication of subsequent poor
chlorpropamide response, for the highest figure in the excellent group was
424 mg./100 ml. and the highest in the failure group 375 mg./100 ml. Secondly,
the treatment period B.S.L. mean (6th-lOth day) was below 165 mg./100 ml.
in all patients whose eventual control with chlorpropamide was satisfactory.
In ordinary clinical practice, however, carrying out three blood sugar
estimations daily during a five-day control period and five-day treatment period
is not practicable. We, therefore, wished to see if any single blood sugar reading
taken routinely during treatment might give as good an estimate of B.S.L. control
on chlorpropamide. It was supposed that should a patient be taken into hospital
and placed on diet alone for one day, the fasting B.S.L. on the second day of
diet might be used as a practical if rather crude representation of the control
period. We, therefore, plotted this reading for each individual comparing it with
the fasting B.S.L. on the eighth day of chlorpropamide treatment. The scatter
here, however, was too great to compare with the original plot, but on the tenth
46day of treatment with 500 mgs. chlorpropamide, which is illustrated in Fig. 2,
there was a close agreement with the original. All patients showing excellent or
good responses after three months' treatment with chlorpropamide again fell into
a rectangle and no matter what the fasting B.S.L. was before treatment, by the
tenth day of chlorpropamide treatment all were below 165 mg./100 ml. and all
other patients with inferior responses had levels above this.
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Fig. 2-Comparison of fasting B.S.L. on second day of control period and the
fasting B.S.L. on the tenth day of treatment on chlorpropamide 500 mg. daily in
forty patients whose final assessment after three months is shown by symbols.-
CLINICAL RESPONSE.
Excellent or Good Group: Intermediate Group: Failures:
* Still on chlorpropamide. X Fair control. H With ketosis.
O Off chlorpropamide. * Poor control. 0 Without ketosis.
DiscusSION.
The action of sulphonyl urea drugs differs from that of insulin in that not all
diabetic patients respond to these compounds.
Reference has already been made to the difficulties encountered in the selection
of diabetics suitable for chlorpropamide treatment. The "selection test" as used
by Cannessa, et al. (1959), and the "response test" of Marble (1958) employed by
Hadley, et al. (1959), occasionally have both shown results discrepant with the
observed outcome of chlorpropamide treatment. We have been unable to find
any correlation between the profile or blood sugar levels of the initial glucose
tolerance test and the subsequent response category in chlorpropamide-treated
diabetics (Boyd and Grant, 1960). It has indeed been suggested that the only
reliable guide to assessing chlorpropamide response in any diabetic patient is by
clinical trial.
47In the present study the conclusion previously reached that high initial fasting
and average daily blood sugar levels do not preclude good clinical control with
chlorpropamide is further confirmed, following three months' survelliance of a
larger series of patients. That a progressive fall in average daily blood sugar
occurs over a period of five-eight days treatment (Grant and Boyd, 1960) is
similarly verified. Although Lee, et al. (1959), state that the maximum response
to chlorpropamide may be delayed until four weeks or longer, no patient in this
series who failed at ten days showed a later response to therapy.
On comparison of Figs. 1 and 2 the similarity of scatter is very evident,
suggesting that the fasting blood sugar level on the tenth day of treatment can
be taken as representing the established effect of 500 mgs. of chlorpropamide,
a dosage level accepted as adequate (Hamwi, et al. (1959), Knick, et al. (1959),
and others). Indeed, Cardonnet, et al. (1959), suggests that a dosage of 750 mgs.
daily should not be exceeded. The conclusion is reached, therefore, that all
patients with excellent or good eventual responses will be expected to have a
fasting blood sugar on the tenth day of treatment, below 165 mg./100 ml.
Analysis of the patients who showed an inferior response to chlorpropamide
presents many problems. The answer to these gets close to solving the problem
of the fundamental action of sulphonyl urea drugs in the dialbetic patient.
The two patients in the fair category had fasting blood sugars on the tenth
day of treatment of just over 180 mg./100 ml. and 310 mg./10: ml. respectively,
while that of the poor response patient was 190 mg./100 ml. (Fig. 2). In Fig. 1
the treatment period B.S.L. mean showed a comparable picture in regard to the
"fair" and "poor" responses. Of the two "fair" cases, the lower of the two,
whose reading fell just above the excellent category response limit, was eating
outside her diet, and on strict diet very probably would have fallen into the
excellent or good response group. The other "fair" response patient was 170
per cent. of ideal weight, while the patient with a "poor" response was over-
weight by 54 per cent. This is in agreement with the previous observation that
obese patients tend to have an inferior response to chlorpropamide, requiring
higher dosage than those approaching their norm in weight (Grant and Boyd,
1959).
Of the non-ketotic failures, one patient was 200 per cent. of ideal weight and
could not be controlled on chlorpropamide 1,000 mgs. daily. On the other hand,
the other two 'non-ketotic' failures were only 115 and 83 per cent. ideal weight
respectively. It is very difficult to explain what common feature prevented these
three patients from responding satisfactorily. The two latter patients required
46 and 40 units of insulin daily for eventual stabilisation and since they had
shown a trace of acetone on previous occasions it is probable that they were
basically ketotic patients. The other non-ketotic failure probably was of the
verv obese resistant type, being 200 per cent. of ideal weight.
The 450 regression line in Fig. 2 has been passed by four patients whose fasting
B.S.L. was higher on the tenth day of chlorpropamide treatment than it was
before the start of therapy. Only one of these was a ketotic failure patient; the
other two ketotic failures falling equidistant below the regression line. It would
48appear, therefore, that partial control of a high blood sugar level in the ketotic
patient by chlorpropamide is of little effect in counteracting the ketotic tendency.
It would seem from the evidence presented that the most important determinant
of success or failure of response to sulphonyl urea drugs appears to be ketosis,
a diabetic effect not adequately counteracted by these compounds.
SUMMARY AND CONCLUSIONS.
A study comprising forty diabetic patients treated on 500 mgs. chlorpropamide
daily is described. The control period mean B.S.L. plotted against the treatment
period mean B.S.L. showed a definite relationship to the patient's response
category after three months' treatment. The plot of the fasting B.S.L. on the
second day of diet alone against the fasting B.S.L. on the tenth day of
chlorpropamide treatment gave a very similar result.
The following conclusions are reached: -
(1) A high initial fasting or average daily B.S.L. does not preclude a good or
excellent response to chlorpropanmide.
(2) The fasting B.S.L. on the tenth day of treatment can be taken as represent-
ing the established effect of the drug and used as a criterion of future
response. All patients in this series with an excellent or good eventual
response to chlorpropamide had a fasting B.S.L. below 165 mg./100 ml.
at this stage of treatment.
(3) Fair to poor responses are usually due to marked obesity with or without
excessive dietary intake.
(4) Failure of response in patients of normal or subnormal weight is usually
related to ketosis. Chlorpropamide nmay decrease the blood sugar in such
patients but does not appear to influence the ketotic tendency.
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